This is also in line with what was observed in another clinical trial (NCT01277757), enrolling advanced breast cancer patients with PIK3CA/Akt1 or PTEN mutations or loss, where the AKT inhibitor, MK-2206, showed limited clinical activity [33]. This evidence concerns the gene PIK3CA and breast cancer.